Stock listing
NASDAQ:BYSI BeyondSpring, Inc. Stock
Home listing (NASDAQ) of BeyondSpring, Inc.
Follow BeyondSpring, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BYSI
$0.33 USD -0.11 (-24.5%)
Close on Nov 20, 2026
- Day range
- $0.299 – $0.455 USDNov 20, 2026
- Volume
- 71,000 sharesNov 20, 2026
- Market cap
- $13.57M USDAt the close on Nov 20, 2026 · price × 41.12M shares outstanding
- 52-week range
- $0.299 – $2.44 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $233,324 USDMedian day 44,855 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BYSI · Home | $0.33 USD | -0.107 (-24.5%) | 71,000 | $0.436 | $0.455 | $0.299 | $0.437 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BYSI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.33 | -0.107 | -24.5% | $0.436 | $0.455 | $0.299 | 71,000 | |
| $0.437 | -0.016 | -3.5% | $0.447 | $0.488 | $0.437 | 33,300 | |
| $0.453 | -0.107 | -19.1% | $0.55 | $0.55 | $0.452 | 52,700 | |
| $0.56 | -0.019 | -3.3% | $0.581 | $0.589 | $0.555 | 13,600 | |
| $0.579 | -0.022 | -3.7% | $0.55 | $0.615 | $0.55 | 61,400 | |
| $0.601 | 0.00 | 0.0% | $0.59 | $0.627 | $0.59 | 33,200 | |
| $0.601 | -0.043 | -6.7% | $0.601 | $0.665 | $0.601 | 47,900 | |
| $0.644 | +0.064 | +11.0% | $0.596 | $0.70 | $0.588 | 78,300 | |
| $0.58 | -0.037 | -6.0% | $0.592 | $0.65 | $0.555 | 72,300 | |
| $0.617 | -0.009 | -1.4% | $0.602 | $0.65 | $0.602 | 43,200 | |
| $0.626 | -0.006 | -0.9% | $0.632 | $0.673 | $0.601 | 34,700 | |
| $0.632 | -0.047 | -6.9% | $0.698 | $0.698 | $0.58 | 93,300 | |
| $0.679 | +0.058 | +9.3% | $0.552 | $0.746 | $0.552 | 176,000 | |
| $0.621 | -0.185 | -23.0% | $0.77 | $0.82 | $0.589 | 235,900 | |
| $0.806 | +0.162 | +25.2% | $0.629 | $0.897 | $0.625 | 1,483,100 | |
| $0.644 | +0.127 | +24.6% | $0.497 | $0.675 | $0.497 | 217,900 | |
| $0.517 | -0.008 | -1.5% | $0.54 | $0.565 | $0.49 | 31,100 | |
| $0.525 | +0.063 | +13.6% | $0.481 | $0.575 | $0.479 | 24,900 | |
| $0.462 | +0.002 | +0.4% | $0.468 | $0.518 | $0.46 | 41,200 | |
| $0.46 | +0.029 | +6.7% | $0.43 | $0.476 | $0.43 | 52,000 | |
| $0.431 | -0.014 | -3.1% | $0.449 | $0.45 | $0.423 | 19,800 | |
| $0.445 | -0.051 | -10.3% | $0.506 | $0.59 | $0.422 | 73,000 | |
| $0.496 | -0.027 | -5.2% | $0.559 | $0.559 | $0.473 | 37,300 | |
| $0.523 | +0.01 | +1.9% | $0.50 | $0.56 | $0.50 | 65,600 | |
| $0.513 | -0.046 | -8.2% | $0.55 | $0.571 | $0.50 | 32,400 | |
| $0.559 | -0.023 | -4.0% | $0.577 | $0.602 | $0.559 | 11,800 | |
| $0.582 | -0.005 | -0.9% | $0.59 | $0.619 | $0.573 | 35,100 | |
| $0.587 | -0.02 | -3.3% | $0.60 | $0.635 | $0.571 | 36,500 | |
| $0.607 | -0.009 | -1.5% | $0.62 | $0.645 | $0.601 | 53,400 | |
| $0.616 | +0.01 | +1.7% | $0.598 | $0.66 | $0.59 | 38,000 | |
| $0.606 | -0.003 | -0.5% | $0.59 | $0.67 | $0.59 | 57,700 | |
| $0.609 | -0.036 | -5.6% | $0.63 | $0.67 | $0.601 | 60,200 | |
| $0.645 | -0.047 | -6.8% | $0.68 | $0.692 | $0.626 | 101,700 | |
| $0.692 | -0.094 | -12.0% | $0.762 | $0.77 | $0.692 | 116,300 | |
| $0.786 | -0.001 | -0.1% | $0.722 | $0.833 | $0.722 | 94,300 | |
| $0.787 | -0.027 | -3.3% | $0.789 | $0.849 | $0.784 | 69,400 | |
| $0.814 | +0.044 | +5.7% | $0.756 | $0.844 | $0.719 | 68,400 | |
| $0.77 | -0.003 | -0.4% | $0.70 | $0.85 | $0.70 | 266,200 | |
| $0.773 | -0.347 | -31.0% | $0.804 | $0.83 | $0.57 | 2,421,600 | |
| $1.12 | +0.343 | +44.1% | $0.751 | $1.14 | $0.751 | 8,196,700 | |
| $0.777 | +0.052 | +7.2% | $0.718 | $0.79 | $0.718 | 15,600 | |
| $0.725 | -0.002 | -0.3% | $0.727 | $0.768 | $0.724 | 17,600 | |
| $0.727 | -0.013 | -1.8% | $0.748 | $0.763 | $0.712 | 13,400 | |
| $0.74 | 0.00 | 0.0% | $0.73 | $0.756 | $0.73 | 15,700 | |
| $0.74 | -0.01 | -1.3% | $0.73 | $0.77 | $0.719 | 32,000 | |
| $0.75 | +0.041 | +5.8% | $0.713 | $0.76 | $0.713 | 45,300 | |
| $0.709 | 0.00 | 0.0% | $0.708 | $0.732 | $0.704 | 37,200 | |
| $0.709 | -0.042 | -5.6% | $0.737 | $0.761 | $0.701 | 35,700 | |
| $0.751 | -0.009 | -1.2% | $0.737 | $0.80 | $0.737 | 18,900 | |
| $0.76 | -0.004 | -0.5% | $0.753 | $0.789 | $0.747 | 30,900 | |
| $0.764 | -0.003 | -0.4% | $0.779 | $0.779 | $0.711 | 95,100 | |
| $0.767 | +0.138 | +21.9% | $0.609 | $0.79 | $0.609 | 846,500 | |
| $0.629 | +0.009 | +1.5% | $0.62 | $0.63 | $0.605 | 39,800 | |
| $0.62 | +0.002 | +0.3% | $0.622 | $0.632 | $0.604 | 31,000 | |
| $0.618 | -0.004 | -0.6% | $0.628 | $0.648 | $0.60 | 26,900 | |
| $0.622 | +0.011 | +1.8% | $0.641 | $0.65 | $0.622 | 42,300 | |
| $0.611 | +0.008 | +1.3% | $0.603 | $0.648 | $0.603 | 40,100 | |
| $0.603 | -0.018 | -2.9% | $0.608 | $0.649 | $0.60 | 52,600 | |
| $0.621 | -0.044 | -6.6% | $0.639 | $0.663 | $0.612 | 55,800 | |
| $0.665 | +0.025 | +3.9% | $0.61 | $0.67 | $0.61 | 113,600 | |
| $0.64 | -0.05 | -7.2% | $0.682 | $0.696 | $0.566 | 289,600 | |
| $0.69 | -0.03 | -4.2% | $0.70 | $0.72 | $0.688 | 35,200 | |
| $0.72 | +0.011 | +1.6% | $0.71 | $0.774 | $0.71 | 44,410 | |
| $0.709 | -0.011 | -1.5% | $0.70 | $0.722 | $0.70 | 26,923 | |
| $0.72 | 0.00 | 0.0% | $0.72 | $0.745 | $0.70 | 59,200 | |
| $0.72 | -0.002 | -0.3% | $0.70 | $0.763 | $0.70 | 36,100 |
- Ticker
- NASDAQ:BYSI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 13, 2026
BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update
Latest deck · Nov 13, 2026
Investor Presentation (November 2026)
Investor deck · 14 slides
Latest news
BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update
Nov 13, 2026
Closed $0.579 (-3.7%) on Nov 16, 2026
FDA Fast Track designation represents an important regulatory milestone for the Plinabulin and docetaxel combination as an anticancer regimen in…
Sep 29, 2026
Closed $0.773 (-31.0%) on Sep 29, 2026
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
Sep 29, 2026
Closed $0.773 (-31.0%) on Sep 29, 2026
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
Aug 14, 2026
Closed $0.712 (-15.1%) on Aug 17, 2026
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
Jun 4, 2026
Closed $1.71 (-1.7%) on Jun 4, 2026
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
Jun 2, 2026
Closed $1.70 (-2.3%) on Jun 2, 2026
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
May 18, 2026
Closed $1.40 (+2.6%) on May 18, 2026
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
Closed $1.45 (+4.3%) on May 13, 2026
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
Apr 22, 2026
Closed $1.63 (-6.3%) on Apr 22, 2026
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
Mar 30, 2026
Closed $1.62 (+1.3%) on Mar 30, 2026
BeyondSpring, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 101 in all · newest Nov 13, 2026 · oldest 2019
- Calls
- 3 calls with a replay · 3 with a transcript · latest Apr 14, 2022
- Decks
- 35 decks · latest Nov 13, 2026
Where BeyondSpring, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BYSI · Home listing · This page | NASDAQ | United States | USD |
| BOATS:BYSI | BOATS | United States | USD |
Valuation
P/E 0.3× against a median of 14.6×: the lowest of 2 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $12.99M USD
- P/E
- 0.3×
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.31
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BeyondSpring, Inc. · NASDAQ:BYSI | US$13.57M | US$12.99M | 0.3× | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| TaiwanJ Pharmaceuticals Co., Ltd. · TPEX:6549 | US$13.69M | US$11.86M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| Actuate Therapeutics, Inc. · NASDAQ:ACTU | US$13.60M | US$11.50M | n/a | n/a | n/a | n/a | n/a | n/a | 1.75 |
| Acumen Pharmaceuticals, Inc. · NASDAQ:ABOS | US$13.49M | −US$38.84M | n/a | n/a | n/a | 0.4× | n/a | 0.8× | 1.45 |
| Pharma Equity Group A/S Class A · OMXCOP:PEG | US$13.47M | US$15.05M | n/a | n/a | 52.7× | 3.6× | n/a | 0.4× | n/a |
| BioInvent International AB · OMXSTO:BINV | US$13.45M | −US$6.62M | n/a | −1.7× | n/a | 0.7× | n/a | 0.1× | n/a |
| Thalia Therapeutics PLC · LSE:THAT | US$13.36M | US$11.39M | n/a | 1,199× | n/a | 4.2× | n/a | 0.0× | n/a |
| Celyad Oncology SA · EURONEXT:CYAD | US$13.31M | US$13.21M | 14.6× | 573× | n/a | 9.7× | n/a | 0.0× | n/a |
| Defence Therapeutics Inc Class A · CSE:DTC | US$13.27M | US$13.16M | n/a | n/a | n/a | 5.4× | n/a | 0.5× | 0.74 |
| Tvardi Therapeutics, Inc. · NASDAQ:TVRD | US$13.22M | −US$9.05M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.89 |
| Diamyd Medical AB Class B · OMXSTO:DMYD_B | US$13.22M | −US$16.66M | n/a | −357× | n/a | 0.6× | n/a | 0.0× | n/a |
| Median of the others | US$13.40M | US$11.45M | 14.6× | 286× | 52.7× | 3.6× | 0.0× | 1.60 |
Team and board
Officers
| Officer | Role |
|---|---|
| Min Qiu | Chief Executive Officer |
| Na Li | Chief Financial Officer |
| Helen Li | VP, Clinical Science |
| John Mao | SVP, Development |
| Joy Jia | VP, Finance |
| June Lu | Chief Scientific Officer |
| Lan Huang | Co-founder & Chairman |
Board
| Director | Role |
|---|---|
| Lan Huang | Co-founder & Chairman |
| Brendan Delaney | Director |
| Jiangwen Majeti | Director |
| Matthew Kirkby | Director |
| Patrick Fabbio | Director |
| Sihai Xu | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| BeyondSpring (NASDAQ:BYSI) Q4 2021 Earnings Call | Thu, Apr 14, 2022 · 8:00 AM ET | Replay |
| BeyondSpring (NASDAQ:BYSI) Q2 2021 Earnings Call | Fri, Sep 10, 2021 · 8:00 AM ET | Replay |
| BeyondSpring (NASDAQ:BYSI) Q4 2020 Earnings Call | Fri, Apr 30, 2021 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 | −3.7% |
| Q2 2026 | Aug 14, 2026 | −28.5% |
| Q1 2026 | May 6, 2026 | −1.4% |
| Q3 2025 | Nov 12, 2025 | −6.4% |
| Q2 2025 | Aug 13, 2025 | 0.0% |
| Q1 2025 | Apr 30, 2025 | +15.5% |
| Q3 2024 | Nov 27, 2024 | +4.3% |
| Q2 2024 | Aug 29, 2024 | +3.0% |
| Q1 2024 | May 1, 2024 | +7.5% |
| Q3 2023 | Dec 21, 2023 | −3.1% |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Jul 10, 2023 | +0.9% |
| Q1 2023 | Apr 18, 2023 · After close | −20.6% |
| Q3 2022 | Dec 22, 2022 | −12.0% |
| Q2 2022 | Sep 9, 2022 | +1.3% |
| Q1 2022 | Apr 14, 2022 · Before open | −9.9% |
| Q3 2021 | Dec 30, 2021 · Before open | +6.4% |
| Q2 2021 | Sep 10, 2021 · Before open | +0.5% |
| Q1 2021 | Jun 16, 2021 · Before open | −6.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 14 slides | Nov 13, 2026 |
| Investor Presentation (October 2026) | Investor deck | 26 slides | Oct 25, 2026 |
| Investor Presentation (September 2026) | Investor deck | 25 slides | Sep 29, 2026 |
| Investor Presentation (August 2026) | Investor deck | 37 slides | August 2026 |
| Investor Presentation (July 2026) | Investor deck | 39 slides | July 2026 |
| Investor Presentation (June 2026) | Investor deck | 39 slides | June 2026 |
| Investor Presentation (April 2026) | Investor deck | 39 slides | Apr 22, 2026 |
| Investor Presentation (April 2026) | Investor deck | 38 slides | April 2026 |
| Investor Presentation (March 2026) | Investor deck | 43 slides | March 2026 |
| IO 360 Summit 2026 | Conference | 19 slides | Feb 11, 2026 |
All 35 decks
IPO
Priced at US$20.00 a share on Mar 8, 2017.
- Price
- US$20.00 a share
- Shares offered
- 174,286 ordinary shares
- Offering size
- US$3.5 million
- Underwriters' option
- Up to 26,141 more shares
- Underwriter
- Rodman & Renshaw
- Shares delivered
- On or about Mar 14, 2017
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 30, 2016 |
| Filed publicly | Nov 15, 2016 |
| Amended 4 times | Newest Mar 8, 2017 |
| Shares registered with an exchange | Mar 6, 2017 |
| Declared effective by the SEC | Mar 8, 2017 |
| Final prospectus, with the price | Mar 9, 2017 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 9, 2017 |
| EFFECT · Notice that a registration is effective | Mar 8, 2017 |
| F-1MEF · Registration of more shares for the same offering | Mar 8, 2017 |
| CERTNAS · Nasdaq's certificate of listing | Mar 8, 2017 |
| F-1/A · Registration statement, amended | Mar 8, 2017 |
| CORRESP · Letter to the SEC | Mar 6, 2017 |
| CORRESP · Letter to the SEC | Mar 6, 2017 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 6, 2017 |
| CORRESP · Letter to the SEC | Mar 2, 2017 |
| F-1/A · Registration statement, amended | Mar 2, 2017 |
All 26 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Mar 1, 2017 |
| FWP · Free writing prospectus | Feb 28, 2017 |
| CORRESP · Letter to the SEC | Feb 28, 2017 |
| F-1/A · Registration statement, amended | Feb 28, 2017 |
| UPLOAD · Letter from the SEC | Feb 17, 2017 |
| F-1/A · Registration statement, amended | Feb 7, 2017 |
| UPLOAD · Letter from the SEC | Nov 15, 2016 |
| CORRESP · Letter to the SEC | Nov 15, 2016 |
| F-1 · Registration statement | Nov 15, 2016 |
| DRSLTR · Letter to the SEC with a draft | Oct 25, 2016 |
| DRS/A · Draft registration statement, amended | Oct 25, 2016 |
| UPLOAD · Letter from the SEC | Sep 29, 2016 |
| DRSLTR · Letter to the SEC with a draft | Sep 19, 2016 |
| DRS/A · Draft registration statement, amended | Sep 19, 2016 |
| UPLOAD · Letter from the SEC | Jul 29, 2016 |
| DRS · Draft registration statement | Jun 30, 2016 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 9, 2017
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1.35M | 1.35M | 180.0K | 0 | 0 | 0 | 0 |
| Cost of revenue | 87.0K | 285.0K | 302.0K | 77.0K | 77.0K | 48.0K | 32.0K | 18.0K | ||
| Gross profit | -87.0K | -285.0K | -302.0K | 1.35M | 1.35M | 180.0K | -77.0K | -48.0K | -32.0K | -18.0K |
| Research and development | 4.39M | 2.64M | 7.27M | 25.6M | 36.9M | 41.8M | 31.3M | 51.6M | 88.9M | 10.4M |
| Selling, general and administrative | 4.56M | 6.11M | 7.81M | 13.0M | 30.7M | 22.6M | 8.96M | 5.93M | 9.05M | 1.93M |
| Operating income | -8.95M | -8.75M | -15.1M | -37.2M | -66.2M | -64.2M | -40.3M | -57.5M | -98.0M | -12.4M |
| Depreciation and amortization | 87.0K | 285.0K | 302.0K | 232.0K | 61.0K | 77.0K | 77.0K | 48.0K | 32.0K | 18.0K |
| EBITDA | -8.86M | -8.47M | -14.8M | -37.0M | -66.2M | -64.1M | -40.2M | -57.5M | -97.9M | -12.3M |
| Interest expense | 0 | 17.0K | 87.0K | 85.0K | 206.0K | 71.0K | 1.59M | 177.0K | ||
| Income before tax | -8.63M | -8.77M | -13.9M | -36.1M | -64.6M | -63.8M | -40.3M | -57.5M | -96.4M | -12.5M |
| Income tax | 90.0K | 96.0K | -92.0K | 163.0K | 3.57M | 0 | 0 | -2.68M | -6.22M | -358.0K |
| Net income | -1.01M | -11.1M | -21.0M | -33.3M | -64.2M | -61.0M | -38.1M | -54.9M | -91.8M | -12.0M |
| Earnings per share, basic | -0.02 | -0.28 | -0.54 | -0.85 | -1.64 | -2.03 | -1.55 | -2.42 | -4.40 | -0.75 |
| Earnings per share, diluted | -1.64 | -2.03 | -1.55 | -2.42 | -4.40 | -0.75 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 2.97M | 2.92M | 5.40M | 34.4M | 41.6M | 109.5M | 35.9M | 3.89M | 27.5M | 11.7M |
| Short-term investments | 1.00M | 0 | 193.0K | 2.87M | 30.7M | 0 | 0 | 3.07M | ||
| Receivables | 481.0K | |||||||||
| Inventory | 1.21M | 799.0K | ||||||||
| Current assets | 20.9M | 28.6M | 18.4M | 38.5M | 75.1M | 113.4M | 40.9M | 5.87M | 32.3M | 14.7M |
| Property, plant and equipment | 155.0K | 239.0K | 317.0K | 1.87M | 1.42M | 184.0K | 209.0K | 282.0K | 123.0K | 80.0K |
| Total assets | 25.9M | 34.3M | 24.8M | 46.2M | 81.6M | 117.0M | 44.6M | 7.06M | 32.8M | 14.9M |
| Accounts payable | 256.0K | 295.0K | 561.0K | 1.08M | 1.66M | 2.22M | 2.54M | 9.59M | 3.38M | 444.0K |
| Current liabilities | 13.6M | 11.0M | 7.96M | 7.35M | 15.2M | 13.8M | 10.1M | 16.4M | 4.79M | 2.61M |
| Long-term debt | 0 | 2.17M | 1.44M | |||||||
| Total debt | 320.0K | 589.0K | 847.0K | 0 | 1.57M | 2.17M | 1.44M | 210.0K | ||
| Total liabilities | 49.9M | 48.6M | 48.3M | 49.2M | 55.3M | 25.2M | 13.4M | 16.4M | 4.79M | 2.61M |
| Shareholders' equity | -32.2M | -32.9M | -26.8M | -5.98M | 26.7M | 88.3M | 30.3M | -7.77M | 27.1M | 12.2M |
| Shares outstanding | 41.1M | 40.3M | 39.0M | 39.0M | 38.9M | 39.1M | 27.9M | 23.2M | 22.5M | 16.9M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -19.8M | -16.4M | -16.5M | -27.5M | -47.2M | -43.7M | -48.2M | -40.0M | -28.8M | -13.7M |
| Capital spending | -50.0K | -224.0K | -100.0K | -34.0K | -2.84M | -52.0K | -4.00K | -207.0K | -76.0K | -64.0K |
| Free cash flow | -19.8M | -16.7M | -16.6M | -27.5M | -50.1M | -43.8M | -48.2M | -40.2M | -28.9M | -13.8M |
| Cash from investing | 10.8M | -12.0M | -100.0K | 17.6M | -20.4M | -52.0K | -4.00K | 2.87M | -3.15M | -64.0K |
| Cash from financing | 4.97M | 26.8M | 4.00K | 3.43M | 1.00K | 117.8M | 80.2M | 13.2M | 47.7M | 14.7M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 69.5M | 14.0M | 50.5M | 15.3M | ||||||
| Change in cash | -3.91M | -1.70M | -16.6M | -7.23M | -67.9M | 73.6M | 32.0M | -23.6M | 15.8M | 866.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 13, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Oct 6, 2026 | Acquisition or disposal | SEC |
| 8-K · Current report | Oct 2, 2026 | Current report | SEC |
| 8-K · Current report | Sep 29, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Sep 29, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 18, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Sep 3, 2026 | Meeting notice | SEC |
Show 200 filings
This page holds 200 of 266 filings. Open Filings
Cap table
Built by 6ix from BeyondSpring, Inc.’s releases · as of Sep 30, 2026
- Common shares
- 41,119,820
- Fully diluted
- 41,119,820
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 41,119,820 | Sep 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 41,119,820 |
| Sep 30, 2026 | 41,409,059 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Brendan Delaney Other companies: Whitehawk Therapeutics, Inc. (See remarks, Director · Apr 1, 2022 – Mar 1, 2023 · Past) | Director · Since at least Dec 31, 2024 |
| Helen Li | VP, Clinical Science · Since at least Nov 5, 2026 |
| Jiangwen Majeti | Director · Since at least Dec 31, 2024 |
| John Mao | SVP, Development · Since at least Jun 4, 2026 |
| Joy Jia | VP, Finance · Since at least Nov 5, 2026 |
| June Lu | Chief Scientific Officer · Since at least Jun 4, 2026 |
| Lan Huang | Co-founder & Chairman · Since at least Dec 31, 2024 |
| Matthew Kirkby | Director · Since at least Dec 31, 2024 |
| Min Qiu | Chief Executive Officer · Since at least Jul 1, 2026 |
| Na Li | Chief Financial Officer · Since at least Jul 1, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Patrick Fabbio | Director · Since at least Nov 5, 2026 |
| Sihai Xu | Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about BeyondSpring, Inc.